Live Breaking News & Updates on Interim Chief Scientific Officer

Stay updated with breaking news from Interim chief scientific officer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Welsh restrictions on LGBT stem cell donation to be lifted

Welsh restrictions on LGBT stem cell donation to be lifted
attitude.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from attitude.co.uk Daily Mail and Mail on Sunday newspapers.

United Kingdom , Eluned Morgan , Tracey Rees , Welsh Blood Service , Welsh Government , Individualised Risk , Social Services , Interim Chief Scientific Officer ,

Liminal BioSciences Provides R&D Update

/PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), announced today that the Company has nominated a lead. ....

United Kingdom , Bruce Pritchard , Liminal Biosciences Inc , Fairhaven Pharmaceuticals Inc , World Health Organisation , Agonist Development Program , Antagonist Development Program , Market Watch Research , Chief Executive Officer , Watch Research , Future Market Insights , Gary Bridger , Interim Chief Scientific Officer , Study Results , Liminal Biosciences Inc ,

Liminal BioSciences Inc.: Liminal BioSciences Provides R&D Update

LMNL6326 nominated as lead preclinical candidate for OXER1 antagonist development program, targeting the treatment of eosinophil-driven diseasesAdvancement of clinical trial application (CTA) ....

United Kingdom , Shrinal Inamdar , Bruce Pritchard , Kaitlin Gallagher , Exchange Commission , World Health Organisation , Market Watch Research , Securities Exchange , Fairhaven Pharmaceuticals Inc , Liminal Biosciences Inc , Agonist Development Program , Antagonist Development Program , Prnewswire Liminal Biosciences Inc , Chief Executive Officer , Watch Research , Future Market Insights , Gary Bridger , Interim Chief Scientific Officer , Study Results , About Liminal Biosciences , Securities Act , Securities Exchange Act , Liminal Bioscience , Nasdaq Listing Rule , Nasdaq Capital Market , Canadian Securities Administrators ,

Liminal BioSciences (LMNL) Provides R&D Update

Liminal BioSciences (LMNL) Provides R&D Update
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United Kingdom , Bruce Pritchard , Liminal Biosciences Inc , Market Watch Research , Fairhaven Pharmaceuticals Inc , World Health Organisation , Agonist Development Program , Exchange Commission , Antagonist Development Program , Securities Exchange , Chief Executive Officer , Watch Research , Future Market Insights , Interim Chief Scientific Officer , Study Results , Securities Act , Securities Exchange Act , Liminal Bioscience , Nasdaq Listing Rule , Nasdaq Capital Market , Canadian Securities Administrators , Annual Report ,

Liminal BioSciences Reports Fourth Quarter and Year Ended 2022 Financial Results

CTA-enabling work on track to seek approval to commence Phase 1 clinical trial of LMNL6511 during the second half of 2023 Addition of GPR40 agonist discovery. ....

United Kingdom , Pointe Claire , Bruce Pritchard , Nicole Rusaw , Antagonist Development Plan , Agonist Development Plan , Liminal Biosciences Inc , Nasdaq Capital , Chief Financial Officer , Gary Bridger , Interim Chief Scientific Officer , Chief Executive Officer , Strategic Advisor , Interim Chief Scientific , Nasdaq Capital Market , Nasdaq Listing Rule , Year Ended December , Liminal Biosciences Inc ,